Recurrent High Risk Myelodysplastic Syndrome Not Yet Recruiting Phase 1 Trials for Pembrolizumab (DB09037)

IndicationStatusPhase
DBCOND0092721 (Recurrent High Risk Myelodysplastic Syndrome)Not Yet Recruiting1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03969446Pembrolizumab and Decitabine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome That Is Newly-Diagnosed, Recurrent, or RefractoryTreatment